公开(公告)号：US07779303B2

公开(公告)日：2010-08-17

申请号：US11679434

申请日：2007-02-27

Applicant: Keith Stubbs ,  Madhuri Vemulakonda

Inventor： Keith Stubbs ,  Madhuri Vemulakonda

IPC: G06F11/00

CPC classification number: G06F11/3688

Abstract: A software testing method. In particular implementations, a method includes accessing a first database of one or more bug entries, wherein each bug entry comprises information characterizing a bug, an associated code component, and a test script; and a mapping between the component and one or more scripts that test the code component; for one or more bug entries in the first database, determining if the bug is a new bug; if the bug is not a new bug, determining if the test script is new relative to the bug; and if the bug is a new bug or if the test script is new relative to the bug, accessing a second database of the script-to-component mappings to add a mapping between the test script and the associated code component of a respective bug entry.

Abstract translation: 软件测试方法。 在特定实现中，一种方法包括访问一个或多个错误条目的第一数据库，其中每个错误条目包括表征错误的信息，相关代码组件和测试脚本; 以及组件与测试代码组件的一个或多个脚本之间的映射; 对于第一个数据库中的一个或多个错误条目，确定该bug是否是新的错误; 如果错误不是一个新的错误，确定测试脚本是否相对于该bug是新的; 并且如果错误是新的错误，或者如果测试脚本相对于该错误是新的，则访问脚本到组件映射的第二个数据库，以在测试脚本和相应的错误条目的关联代码组件之间添加映射 。

公开(公告)号：US20100016386A1

公开(公告)日：2010-01-21

申请号：US12438882

申请日：2007-08-31

Applicant: David Vocadlo ,  Ernest McFachern ,  Keith Stubbs ,  Tong-Shuang Li ,  Garrett Whitworth ,  Julia Heinonen ,  Matthew Macauley

Inventor： David Vocadlo ,  Ernest McFachern ,  Keith Stubbs ,  Tong-Shuang Li ,  Garrett Whitworth ,  Julia Heinonen ,  Matthew Macauley

IPC: A61K31/429 ,  C07D513/02 ,  C12Q1/34 ,  A61P25/00 ,  A61P35/00 ,  A61P29/00 ,  A61P37/08 ,  A61P11/00 ,  A61P37/06

CPC classification number: G01N33/6803 ,  C07D513/04 ,  C07D513/14 ,  C07F9/6561 ,  C07H9/06

Abstract: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc

Abstract translation: 本发明提供了用于选择性抑制糖苷酶，化合物前药和包含化合物或药物前体药物的药物组合物的式（I）化合物。本发明还提供了治疗与O-GlcNAcase的缺乏或过度表达有关的疾病和病症的方法， O-GlcNAc的积累或不足

公开(公告)号：US20120316207A1

公开(公告)日：2012-12-13

申请号：US13591927

申请日：2012-08-22

Applicant: David Vocadlo ,  Ernest McEachern ,  Keith Stubbs ,  Tong-Shuang Li ,  Garrett Whitworth ,  Julia Heinonen ,  Matthew Macauley

Inventor： David Vocadlo ,  Ernest McEachern ,  Keith Stubbs ,  Tong-Shuang Li ,  Garrett Whitworth ,  Julia Heinonen ,  Matthew Macauley

IPC: A61K31/429 ,  C07D513/04

CPC classification number: G01N33/6803 ,  C07D513/04 ,  C07D513/14 ,  C07F9/6561 ,  C07H9/06

Abstract: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

Abstract translation: 本发明提供了用于选择性抑制糖苷酶，化合物前药和包括化合物的化合物或前药的药物组合物的式（I）化合物。 本发明还提供了治疗与O-GlcNAcase的缺乏或过度表达相关的疾病和障碍的方法，O-GlcNAc的积累或缺乏。

公开(公告)号：US08334310B2

公开(公告)日：2012-12-18

申请号：US12438882

申请日：2007-08-31

Applicant: David Vocadlo ,  Ernest McEachern ,  Keith Stubbs ,  Tong-Shuang Li ,  Garrett Whitworth ,  Julia Heinonen ,  Matthew Macauley

Inventor： David Vocadlo ,  Ernest McEachern ,  Keith Stubbs ,  Tong-Shuang Li ,  Garrett Whitworth ,  Julia Heinonen ,  Matthew Macauley

IPC: A61K31/429 ,  C07D513/04

CPC classification number: G01N33/6803 ,  C07D513/04 ,  C07D513/14 ,  C07F9/6561 ,  C07H9/06

Abstract: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc

Abstract translation: 本发明提供了用于选择性抑制糖苷酶，化合物前药和包含化合物或药物前体药物的药物组合物的式（I）化合物。本发明还提供了治疗与O-GlcNAcase的缺乏或过度表达有关的疾病和病症的方法， O-GlcNAc的积累或不足

公开(公告)号：US20080209276A1

公开(公告)日：2008-08-28

申请号：US11679434

申请日：2007-02-27

Applicant: Keith Stubbs ,  Madhuri Vemulakonda

Inventor： Keith Stubbs ,  Madhuri Vemulakonda

IPC: G06F11/00

CPC classification number: G06F11/3688

Abstract: A software testing method. In particular implementations, a method includes accessing a first database of one or more bug entries, wherein each but entry comprises information characterizing a bug, an associated code component, and a test script; and a mapping between the component and one or more scripts that test the code component; for one or more bug entries in the first database, determining if the bug is a new bug; if the bug is not a new bug, determining if the test script is new relative to the bug; and if the bug is a new bug or if the test script is new relative to the bug, accessing a second database of the script to component mappings to add a mapping between the test script and the associated code component of a respective bug entry.

Abstract translation: 软件测试方法。 在特定实现中，一种方法包括访问一个或多个错误条目的第一数据库，其中除条目之外的每一个都包括表征错误的信息，相关代码组件和测试脚本; 以及组件与测试代码组件的一个或多个脚本之间的映射; 对于第一个数据库中的一个或多个错误条目，确定该bug是否是新的错误; 如果错误不是一个新的错误，确定测试脚本是否相对于该bug是新的; 如果错误是一个新的错误，或者如果测试脚本是相对于该错误的新脚本，则将脚本的第二个数据库访问到组件映射，以便在测试脚本和相应的错误条目的关联代码组件之间添加映射。

公开(公告)号：US08962664B2

公开(公告)日：2015-02-24

申请号：US13591927

申请日：2012-08-22

Applicant: David Vocadlo ,  Ernest McEachern ,  Keith Stubbs ,  Tong-Shuang Li ,  Garrett Whitworth ,  Julia Heinonen ,  Matthew Macauley

Inventor： David Vocadlo ,  Ernest McEachern ,  Keith Stubbs ,  Tong-Shuang Li ,  Garrett Whitworth ,  Julia Heinonen ,  Matthew Macauley

IPC: A61K31/429 ,  C07D513/04 ,  G01N33/68 ,  C07D513/14 ,  C07F9/6561 ,  C07H9/06

CPC classification number: G01N33/6803 ,  C07D513/04 ,  C07D513/14 ,  C07F9/6561 ,  C07H9/06

Abstract: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

Abstract translation: 本发明提供了用于选择性抑制糖苷酶，化合物前药和包括化合物的化合物或前药的药物组合物的式（I）化合物。 本发明还提供了治疗与O-GlcNAcase的缺乏或过度表达相关的疾病和障碍的方法，O-GlcNAc的积累或缺乏。

公开(公告)号：US08541441B2

公开(公告)日：2013-09-24

申请号：US13057062

申请日：2009-07-31

Applicant: David Jaro Vocadlo ,  Ernest John McEachern ,  Keith Stubbs

Inventor： David Jaro Vocadlo ,  Ernest John McEachern ,  Keith Stubbs

IPC: A61K31/437 ,  C07D221/04

CPC classification number: C07D471/04 ,  C12Q1/34 ,  G01N2500/00

Abstract: The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

公开(公告)号：US20120095033A1

公开(公告)日：2012-04-19

申请号：US13057062

申请日：2009-07-31

Applicant: David Jaro Vocadlo ,  Ernest John Mceachern ,  Keith Stubbs

Inventor： David Jaro Vocadlo ,  Ernest John Mceachern ,  Keith Stubbs

IPC: A61K31/437 ,  A61P27/14 ,  A61P11/06 ,  A61P29/00 ,  A61P11/00 ,  A61P9/10 ,  A61P19/02 ,  A61P25/00 ,  A61P13/12 ,  A61P37/06 ,  A61P1/00 ,  A61P17/06 ,  A61P17/00 ,  A61P25/08 ,  A61P25/28 ,  A61P35/00 ,  A61P25/16 ,  A61P37/08 ,  C12Q1/34 ,  C07D471/04

CPC classification number: C07D471/04 ,  C12Q1/34 ,  G01N2500/00

Abstract: The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

Abstract translation: 本发明提供了用于选择性抑制糖苷酶的化合物（I）的化合物，以及化合物的前药以及包含化合物的化合物或前药的药物组合物。 本发明还提供了治疗与O-GlcNAcase的缺乏或过度表达相关的疾病和障碍的方法，O-GlcNAc的积累或缺乏。